drugset / Trial / NCT01222195
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if lenalidomide and darbepoetin alfa given together will help to control the need for transfusions in patients with low to intermediate risk Myelodysplastic Syndrome (MDS). The safety of this combination will also be studied.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 200 ug | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |